- Home
- HGTY vs AVBP Comparison
HGTY vs AVBP Comparison
Compare HGTY & AVBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HGTY
- AVBP
- Stock Information
- Founded
- HGTY 1984
- AVBP 2021
- Country
- HGTY United States
- AVBP United States
- Employees
- HGTY N/A
- AVBP N/A
- Industry
- HGTY Specialty Insurers
- AVBP
- Sector
- HGTY Finance
- AVBP
- Exchange
- HGTY Nasdaq
- AVBP NYSE
- Market Cap
- HGTY 995.8M
- AVBP 925.7M
- IPO Year
- HGTY N/A
- AVBP 2024
- Fundamental
- Price
- HGTY $9.54
- AVBP $24.85
- Analyst Decision
- HGTY Hold
- AVBP Strong Buy
- Analyst Count
- HGTY 3
- AVBP 5
- Target Price
- HGTY $11.00
- AVBP $36.80
- AVG Volume (30 Days)
- HGTY 65.1K
- AVBP 152.8K
- Earning Date
- HGTY 11-07-2024
- AVBP 02-02-2025
- Dividend Yield
- HGTY N/A
- AVBP N/A
- EPS Growth
- HGTY N/A
- AVBP N/A
- EPS
- HGTY 0.11
- AVBP N/A
- Revenue
- HGTY $1,153,350,000.00
- AVBP N/A
- Revenue This Year
- HGTY $21.17
- AVBP N/A
- Revenue Next Year
- HGTY $14.52
- AVBP N/A
- P/E Ratio
- HGTY $89.70
- AVBP N/A
- Revenue Growth
- HGTY 21.13
- AVBP N/A
- 52 Week Low
- HGTY $7.68
- AVBP $14.35
- 52 Week High
- HGTY $12.35
- AVBP $36.37
- Technical
- Relative Strength Index (RSI)
- HGTY 33.65
- AVBP 38.49
- Support Level
- HGTY $9.16
- AVBP $23.80
- Resistance Level
- HGTY $9.96
- AVBP $27.34
- Average True Range (ATR)
- HGTY 0.25
- AVBP 1.39
- MACD
- HGTY -0.03
- AVBP -0.11
- Stochastic Oscillator
- HGTY 29.17
- AVBP 22.27
About HGTY Hagerty Inc.
Hagerty Inc is a provider of specialty automotive insurance. The company underwrites, sells, and services classic car and enthusiast vehicle insurance policies. Substantial revenue is derived from Commission and fees. Geographically it serves Europe, Canada, and the United States.
About AVBP ARRIVENT BIOPHARMA INC
ArriVent BioPharma Inc is a clinical stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize team's deep drug development experience to maximize the potential of lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.